IRSST - Institut de recherche Robert-Sauvé en santé et en sécurité du travail

Development of markers and validation of diagnostic tools for screening for beryllium-induced hypersensitivity and beryllium disease

Abstract

Known for its high toxicity, beryllium can cause berylliosis, a serious pneumopathy, or chronic beryllium disease. The lymphocyte proliferation test (BeLPT) commonly used for detecting a worker’s sensitivity to this metal offers little predictive value for the risks of contracting berylliosis. Knowing that this disease can take up to 30 years to develop in a sensitized worker, it is essential that a new effective detection tool be developed. By exploring experimental approaches, the research team was able to determine the feasibility of methods for the selective characterization of target cells and the use of protein signatures on blood samples. They also developed a technique for quantifying beryllium in plasma and tested the potential of complexing agents for displacing it and reversing its toxicity in cell cultures. These new tools will allow a follow-up program to be implemented for sensitized workers, mainly by providing a more precise diagnosis of the determination of their exposure to beryllium. It will also be possible to validate actual exposure standards or to determine new ones based on solid foundations.

Additional Information

Type: Project
Number: 0099-4910
Status: Completed
Year of completion: 2007
Team:
  • Michel Fournier (INRS-Institut Armand-Frappier)
  • Alain Fournier (INRS-Institut Armand-Frappier)
  • Jacques Bernier (INRS-Institut Armand-Frappier)
  • Daniel Cyr (INRS-Institut Armand-Frappier)
  • Sébastien Sauvé (Université de Montréal)
  • Jacques Gagnon (Centre de recherche sur les biotechnologies marines)
  • Pauline Brousseau (Biophage Inc.)